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Hyperoxaluria with hyperglycoluria not due to alanine:glyoxylate ami-
notransferase defect: A novel type of primary hyperoxaluria. Considering
the clinical heterogeneity of primary hyperoxaluria type I (PHI) and the
fact that in many instances this diagnosis was made without enzymatic and
immunohistochemical investigation, other disturbances of oxalate metab-
olism than those presently known can be expected in PH1. Using a
gaschromatographic/mass spcctrometric method that allows quantification
of these acids, hyperoxaluria and hyperglycoluria was found repeatedly in
two unrelated patients. The hyperoxaluria was unresponsive to pyridoxinc.
There was no nephrocalcinosis or urolithiasis. In the liver biopsy normal
AGT activity and normal localization of this enzyme in the peroxisome
was found. In one patient abnormal Km and maximal activity and
mozaicism of AGT were excluded. Hyperoxaluria and hyperglycoluria
were also found in other family members, suggesting autosomal dominant
transmission. Although the underlying defect leading to hyperoxaluria and
hyperglycoluria could not be identified in these patients, it is probable that
they represent a separate type of primary hyperoxaluria.
At present two types of genetically-determined primary hyper-
oxaluria (PH) are discerned. In type I (PHI) glyoxylate metabo-
lism in the hepatic peroxisome is impaired as a consequence of
deficient alanine:glyoxylate aminotransferase (AGT) activity; in
2/3 of these patients hyperoxaluria is accompanied by hypergly-
coluria [1]. Measurement of the catalytic activity of AGT and
study of its subcellular localization in liver biopsies from patients
with PHi have demonstrated that the cause of the AGT deficiency
may vary from a diminished catalytic activity of the normally
localized enzyme to a diminished activity due to extraperoxisomal
localization of the enzyme [21. The much more rare type 2 (PH2)
is probably due to a deficiency of a cytosolic enzyme with
D-glycerate dehydrogenase and glycerate reductase activity in the
liver. This type is characterized by an increased urinary excretion
of oxalate and L-glyccratc [3].
We report on two unrelated patients with hyperoxaluria and
hyperglyeoluria and therefore categorized as PHI, in whom AGT
was normally localized in the peroxisomes and had a normal
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catalytic activity. This metabolic error may represent a separate
type of primary hyperoxaluria.
Methods
In the children (patients and their siblings) random urinary
samples and in the adults (their parents, grandparents, aunts and
uncles) 24-hour urine collections were examined. Organic acids,
oxalie acid, glyoxylic acid and glycolic acid were determined as
their trimethylsilyl derivatives by gaschromatography on a capil-
lary column (LP-Sil 19 CB, Chrompack, The Netherlands) using
an HP 5890 gaschromatograph connected to a HP 5972 mass
spectrometer (Hewlett-Packard). Extraction and preparation of
the derivatives was performed as described by Duran et al [4].
3-Phenylbutyric acid was used as an internal standard. Glyoxylie
acid, glycolic acid and oxalic acid appeared in the chromatogram
at 8.66, 9.40 and 13.06 minutes, respectively. Identification of
these compounds was done by mass spectrometry [Library: NIST
(Hewlett-Packard) and Wilhelmina Kinderziekenhuis, Utrecht,
The Netherlands]. The compounds oxalate and glycolate were
quantified using regression lines obtained by injection of different
concentrations of authentic standards. Variability of the method
was 15%. We did not establish normal values in a control
population but used the normal values proposed in the literature
with different methods [5—7]. The values obtained in our patients
were the only ones in that range during an examination of more
than 2,000 urine samples; they were comparable to the values
obtained in a proven ease of classical PHi. Oxalate values were
expressed in j.rmol/mmol creatinine in the children and in j.rmol/24
hr in the adults, glyoxylate always in imol/mmol creatinine. AGT
activity in liver biopsies was determined with a spectrophotomet-
nc technique as described earlier, which allows measurement in
small quantities of tissue [8]. Subcellular localization of AGT was
performed using an immunogold technique for light and electron
microscopy [9]. Samples from both biopsies were incubated for
the cytochemical demonstration of catalase activity with diamino-
benzidine according to Rods, de Prest and de Pestel [10].
Morphomctric analysis of the hepatic peroxisomes was performed
according to Kerckacrt, de Craemer and van Limbergen [11].
Patients
Patient 1, a girl, came to our attention at the age of 12 months
with a history of pronounced growth and weight retardation.
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Table 1. Urinary and plasma oxalic and glycolic acid and AGT activity in the 2 patients
Patient 2
< 6 months
> 6 months
Mean normal value (range)
Age < 6 months
Age > 6 months
PHi patient
(normal renal function) [referencel
ND is not detectable.
Under treatment with pyridoxine
Urine
p.mol/mmol creatinine
463
440
331
812
245
972
1763
685
428
44P
252
147(77—325)
72(38—132)
286—2022
[7J
__________
Glycolic acid
Plasma Urine Plasma
jemol/liter pinol/mmol creatinine pot/liter
198
330
I34
85
71
404
830
112
155k'
748
176
175(63—363)
116(58—245)
AGT activity in
liver tissue
nmol/min/mg protein
9
112
1 to 2
[own control pat.]
Psychomotor development was normal. Besides the marked dys-
trophy (weight 3.5 kg below third percentile) and growth retarda-
tion (height 4 cm below third percentile) there were dysmorphic
features consisting of outstanding, abnormally shaped ears and
slanting of the eyes. There were no other abnormalities. No
indications for intestinal malabsorption were found: serum pro-
teins and lipids were normal as were fecal fat excretion, sweat test
and X-rays of the gastro-intestinal tract. Direct mass spectromet-
nc analysis showed a normal urinary bile acid pattern (M. Duran,
Utrecht, The Netherlands). Glomerular filtration rate was slightly
decreased (inulin clearance 77 ml/min/i.73 m2); i.v. urography
and ultrasonography showed a right kidney that was smaller than
the left, but no nephrocalcinosis or urolithiasis. Ophthalmoscopy
and X-ray of the skeleton were normal. On metabolic investiga-
tion a normal urinary pattern of amino acids was found. Gas
chromatography/mass spectrometry of the organic acids in the
urine, however, revealed an increased amount of oxalic, glyoxylic
and glycolic acid (Table 1). A comparable value was obtained for
oxalic acid with an enzymatic method (P. Divry, Lyon, France).
Plasma oxalate was also increased. Increased values for oxaluria
and glycoluria were found on different occasions; treatment with
pyridoxine, 200 mg/day, during two months did not influence the
oxaluria. With the presumptive diagnosis of PHi, a liver biopsy
was performed which showed normal catalytic activity of AGT
and a normal peroxisomal localization of the enzyme (Fig. I A,
C). Immunoblotting confirmed the presence of normal AGT.
Calciuria was within normal limits for age (calcium/creatiriine
ratio 0.22) as was citraturia (370 mmol/mol creatinine in a 24-hr
specimen). Investigation of the family members revealed hyper-
oxaluria in the father (496 jxmol/24 hr), his sister (1504 jxmol/24
hr) and his mother (556 emol/24 hr) (normal < 170 mol/24 hr).
The aunt of the patient, but not her father and grandmother, also
had hyperglycoluria (410 tmol/mmol creatinine; 95th percentile
for age: 99 jemol/mmol creatinine). Moreover, the father and his
sister, but not the grandmother, suffered from cystinuria. Ultra-
sonography of the kidneys was normal in the mother and the
paternal aunt and grandmother. The father had frequent episodes
of urolithiasis for which one kidney was removed. Urolithiasis in
the remaining kidney was confirmed on ultrasonography. At
present the patient is being treated with citrate in order to prevent
calcium oxalate deposition. Height and weight remain below the
third percentile.
Patient 2, a boy, presented at the age of two months with an
apparent life-threatening event (ALTE). Clinical investigation on
admission was normal but gastro-esophageal reflux was diagnosed
and treated. As in all our patients with ALTE, the amino acid and
organic acid patterns in the urine were investigated. While the
former was normal, the latter revealed an increased excretion of
oxalic, glyoxylic and glycolic acid (Table 1). The hyperoxaluria and
hyperglycoluria were confirmed on several occasions. Plasma
oxalate was increased. Treatment with pyridoxine, 300 mg/day
during two months, resulted in a non-significant decrease of the
oxaluria. Renal function was normal. Ultrasonography and X-ray
of the kidneys did not reveal nephrocalcinosis or urolithiasis. A
liver biopsy was performed which showed a normal catalytic
activity of AUT and a normal localization of the enzyme exclu-
sively in the peroxisomes in multiple areas of the biopsy specimen
(Fig. 1 B, D). The enzymatic activity of AGT with different
concentrations of its substrates L-alanine and L-glyoxylate was
also studied in the liver biopsy: Km as well as maximal AGT
activity were not different from control values (Fig. 2 A, B).
Calciuria was normal (calcium/creatinine ratio 0.25) but citraturia
was markedly elevated (1617 mmol/mol creatinine in a 24-hours
specimen). Investigation of the family members showed hyperox-
aluria in the mother and the maternal grandmother (1280
jrmol/24 hr and 313 emol/24 hr; normal < 170 j.tmol/24 hr) and a
slightly increased glycoluria in the mother (109 jtmol/mmol
creatinine; 95th percentile for age: 99 .tmol/mmol ereatinine).
Patient 1
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Fig. 1. A and B. Hepatocellularperoxisomes (arrowheads), identified by the electron dense diaminobenzidine reaction product after incubation for catalase
activity in patients I and 2 respectively. In patient I the reaction is relatively weak and the peroxisomal matrix contains electron-lucent compartments.
In patient 2 peroxisomes with a tail-like extension (arrowhead) or with an aberrant angular shape (double arrowheads) are present. C and D. A normal
peroxisomal localization of AGT is found after immunolabeling in both patients (C and D from patients 1 and 2, respectively). Colloidal gold particles
(15 nm) are present over the peroxisomal matrix (arrowheads); in patient 1 this matrix contains electron-lucent compartments. Mitoehondria are
indicated by arrows. Magnification in A—D x24,000; scale bar = 0.5 jsm.
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Fig. 2. Enzymatic activity 0fAGT with increasing concentrations of its substrates L-glyoxylate (A) and L-alanine (B) in patient 2. Symbols are: (S) patient;() controls.
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Table 2. Morphometry of hepatic peroxisomes
N peroxisomes measured
d-circle p.m
mean
corr mean
max
above 95th percentile
Axial ratio
mean
max
mm
Volume parameters
Numerical density (Nv; m
Volume density (Vv; %)
Surface density (Sv; jun1)
0.547 0.017
0.675
0.970
0.900 0.026
0.8 18
0.970
0.440
0.120
1.567
0.149
0.494 0.O1T
0.608
1.020
0.817 0.068
0.779
0.926
0.407
0.131
1.251
0.13 1
989
0.525 0.018
0.643
0.940
0.768 0.015k'
0.861
0.995
0.410
0.100 0.009
1.047 0.10
0.110 o.ola
0.433—0.617
0.569—0.717
0.044—0.156
0.499—1.595
0.054—0. 166
Standard error of the mean
Ultrasonography of the kidneys in mother and father was normal.
Treatment with citrate was started. On follow-up, clinical investi-
gation remained normal. It should be mentioned that the mater-
nal grandmother suffered from urolithiasis, the nature of which
could not he defined, and renal failure.
In both patients the morphometric values of the hepatic
peroxisomes were within the range of control livers (Table 2).
Liver biopsy in family members was refused.
Discussion
In both patients the increased urinary excretion of oxalic and
glycolic acid was detected fortuitously because these acids appear
on the chromatogram of organic acids as it is performed by us.
This method also reliably quantifies these acids. The values
observed for oxaluria were two- to sixfold the upper normal limit
Fig. 3. Schematic representation of the metabolic
pathways of glyoiylate, glycolate and oxalate in
the human hepatocyte. Abbreviations are: SPT,
serine:pyruvate aminotransferase; AGT,
alanine:glyoxylate aminotransferase; DAO, D-
amino acid oxidasc; GO, glycolate oxidase; OR,
glyoxylate reductase; LDH, lactate
dehydrogenase; GGT, glutamate:glyoxylate
aminotransferase; GD, glycolate dehydrogenase.
mentioned in the literature for this age group, and were the only
ones in that range among a large number of urine specimens. The
hyperoxaluria was confirmed on several occasions and was not
influenced by high doses of pyridoxine in the first patient and only
slightly in the second one. The hyperglycoluria was also found
repeatedly but was more variable. Plasma oxalate was increased in
both patients. From the biochemical point of view our patients
should be categorized as PHI: the absence of L-glyceric acid in
the urine excluded PH2 and glyeolate excretion is normal in the
different forms of secondary hyperoxaluria, with the exception of
ethylene glycol intoxication [I]. Clinical symptoms suggesting
PHi, mainly nephrocalcinosis and urolithiasis, were absent, but it
is well known that such symptoms and their repercussion on renal
function may appear only later in life [12—14]. Different factors
determine stone formation. It is noted that the father of patient 1,
Patient I
81
Patient 2
76
Adult controls [11, 17]
N 95% confidence limits
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who had relapsing stone formation, had marked hypocitraturia
(58 mmol/mol creatinine), whereas the other family members of
the two patients without urolithiasis had normal citraturia. Con-
sidering the biochemical findings in both our patients, it was
surprising that none of the enzymatic abnormalities found in PHi
and which may vary from diminished activity of normally localized
AGT or absence of the enzyme to diminished activity resulting
from extraperoxisomal location, were observed in the liver biop-
sies [2]. The normal morphometric values of the hepatic peroxi-
somes also differed from classical PHi in which a decrease of
peroxisomal size was constantly found in combination with a
reduced [151 or normal to increased [11, 16, 17] number. Using
the proposed correlation between the size of the peroxisomes and
their functional capacity [181, the results in the present cases
indicated a normal content of the peroxisomal matrix.
Other mechanisms than these well established causes of dimin-
ished AGT activity must therefore be considered. In view of the
concomitant hyperglycoluria and taking into account that in
humans the glyoxylate pathway is the main endogenous source of
oxalate, this error is probably localized in the peroxisomal branch
of glyoxylate metabolism (Fig. 3). As far as AGT is concerned,
other possible causes of a diminished activity of this enzyme could
be an abnormal Km value or AGT mozaicism in which AGT
would be expressed only in a restricted number of hepatocytes;
both possibilities were excluded in the second patient. Another
possibility is a diminished AGT activity as a consequence of a
deficient transport of its substrates alanine or glyoxylate or both
through the peroxisomal membrane. Very little is known about
the transport of these substrates and we were unable to investigate
this in our patients. Theoretically, peroxisomal enzymes other
than AGT could also be involved (Fig. 3). Thus, the deficiency of
glycolate oxidase, a flavoprotein in the peroxisome, would lead to
accumulation and leaking of glycolate into the cytosol where it
would be transformed to oxalate by glycolate dehydrogenase.
Hyperactivity of D-amino acid oxidase in the peroxisome would
also result in hyperoxaluria and hyperglycoluria. All these possi-
bilities need to be investigated in our patients, however, for ethical
reasons a second liver biopsy was not performed until this study.
A deficiency of riboflavin, a co-factor of glycolate oxidase is
improbable as the organic acid pattern in the urine indicates a
normal fatty acid oxidation. Carboligase deficiency, which was
originally proposed as the cause of PHi, has never been demon-
strated in the human and even the identity of this enzyme has
been questioned [1]. Furthermore, there were no biochemical or
hematological indications for thiamine deficiency, which in the rat
may lead to hyperoxaluria as a consequence of diminished carbo-
ligase activity.
In 1986, Gill and Rose described a condition characterized by
urolithiasis, hyperoxaluria and glycoluria, which they separated
from PHi and labeled mild metabolic hyperoxaluria [19]. The
main distinction with PHi was the lower degree of hyperoxaluria.
All patients were male and only sporadic cases were observed. As
no enzymic studies were performed, it is difficult to discuss the
relationship of this condition with that in our patients or even with
PHi.
Whatever the underlying defect, both patients probably repre-
sent a separate type of primary hyperoxaluria. This is not surpris-
ing when one considers the clinical heterogeneity in patients in
whom the diagnosis of PHI was made, often without enzymatic
and immunohistochemical data. As opposed to classical P1-Il,
where the transmission is autosomal recessive, the disorder in our
patients appears to be inherited as an autosomal dominant trait.
The occurrence of cystinuria in the first family is puzzling, but it
should be recalled that both the human AGT gene and the gene
for cystinuria have been mapped to chromosome 2 [20, 21]. In the
family presented here, both disorders seem to be independently
inherited.
Whether our patients will develop urolithiasis and nephrocal-
cinosis is uncertain considering the many factors that determine
stone formation. As oxalate excretion was in the range observed in
classical PHi, we treated both our patients with citrate [22]. A
much longer follow-up is needed for the evaluation of the further
evolution.
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